Morocco
Tuberculosis profile
Population  2013 33 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.8 (0.01–13) 8.6 (0.03–39)
Mortality (HIV+TB only) 0.098 (0.044–0.17) 0.3 (0.13–0.53)
Prevalence  (includes HIV+TB) 43 (18–79) 131 (55–240)
Incidence  (includes HIV+TB) 34 (31–37) 104 (95–112)
Incidence (HIV+TB only) 0.59 (0.44–1.2) 1.8 (1.3–3.7)
Case detection, all forms (%) 85 (79–93)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.5 (0.2–1.1) 12 (7.8–18)
MDR-TB cases among notified pulmonary
TB cases
72 (29–160) 230 (150–340)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 11 993   1 135
Pulmonary, clinically diagnosed 2 428   21
Extrapulmonary 13 145   404
       
Total new and relapse 29 126    
Previously treated, excluding relapses 770    
Total cases notified 29 896    
Among 27 566 new cases:
2 051 (7%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 87 (<1%) 332 (14%) 460
Laboratory-confirmed RR-/MDR-TB cases     108
Patients started on MDR-TB treatment     89
TB/HIV 2013 Number (%)
TB patients with known HIV status 9 484 (32)
HIV-positive TB patients 78 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 78 (100)
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 89
Previously treated cases, excluding relapse, registered in 2012 50
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 30
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 2.7
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 20
% Funded domestically 92%
% Funded internationally 8%
% Unfunded <1%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-22 Data: www.who.int/tb/data